These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. src-specific immune regression of Rous sarcoma virus-induced tumors. Gelman IH; Hanafusa H Cancer Res; 1993 Feb; 53(4):915-20. PubMed ID: 8381333 [TBL] [Abstract][Full Text] [Related]
3. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line. Lansing TJ; Turk BF; Kanner SB; Gilmer TM Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992 [TBL] [Abstract][Full Text] [Related]
4. Two novel variants of the v-src oncogene isolated from low and high metastatic RSV-transformed hamster cells. Tatosyan A; Yatsula B; Shtutman M; Moinova E; Kaverina I; Musatkina E; Leskov K; Mizenina O; Zueva E; Calothy G; Dezélée P Virology; 1996 Feb; 216(2):347-56. PubMed ID: 8607264 [TBL] [Abstract][Full Text] [Related]
5. Transformation of NIH3T3 cells by Rous sarcoma virus occurs with high efficiency in the absence of proviral rearrangements or amplification. Falcone G; Provenzano C; Alemà S; Tatò F Oncogene; 1992 Oct; 7(10):1913-20. PubMed ID: 1328985 [TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells. Maroney AC; Qureshi SA; Foster DA; Brugge JS Oncogene; 1992 Jun; 7(6):1207-14. PubMed ID: 1375718 [TBL] [Abstract][Full Text] [Related]
7. Tumor rejection antigens on BALB3T3 cells transformed by activated oncogenes. Torigoe T; Sato N; Takashima T; Cho JM; Tsuboi N; Qi WM; Hara I; Wada Y; Takahashi N; Kikuchi K J Immunol; 1991 Nov; 147(9):3251-8. PubMed ID: 1919013 [TBL] [Abstract][Full Text] [Related]
8. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630 [TBL] [Abstract][Full Text] [Related]
9. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation. Tian M; Martin GS Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894 [TBL] [Abstract][Full Text] [Related]
10. Immune selection in murine tumors. Ph.d thesis. Svane IM; Engel AM APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251 [TBL] [Abstract][Full Text] [Related]
11. Transformation by p60src with altered N-terminal sequences. Hanafusa H; Garber EA; Hanafusa T Princess Takamatsu Symp; 1986; 17():233-40. PubMed ID: 2843496 [TBL] [Abstract][Full Text] [Related]
12. [Immunobiological characterization of murine LB leukemia and the LBC cell line]. Hajos SE; Mongini C; Waldner C; Sánchez Lockhart M; Gravisaco MJ; Roig I; Fernańdez T; Alvarez E Medicina (B Aires); 1996; 56 Suppl 1():45-56. PubMed ID: 9224974 [TBL] [Abstract][Full Text] [Related]
13. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Newmaster RS; Mylin LM; Fu TM; Tevethia SS Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511 [TBL] [Abstract][Full Text] [Related]
14. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells. Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624 [TBL] [Abstract][Full Text] [Related]
15. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. Bright RK; Shearer MH; Kennedy RC J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411 [TBL] [Abstract][Full Text] [Related]
16. No expression of a Rous sarcoma virus-induced tumor antigen in mammalian cells infected with retroviruses transducing other oncogenes of the src gene family. Kuzumaki N; Yamagiwa S; Oikawa T J Natl Cancer Inst; 1985 Apr; 74(4):889-92. PubMed ID: 2985859 [TBL] [Abstract][Full Text] [Related]
17. Identification of multiple novel polypeptide substrates of the v-src, v-yes, v-fps, v-ros, and v-erb-B oncogenic tyrosine protein kinases utilizing antisera against phosphotyrosine. Kamps MP; Sefton BM Oncogene; 1988 Apr; 2(4):305-15. PubMed ID: 2452398 [TBL] [Abstract][Full Text] [Related]
18. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes. Hevezi P; Alin K; Goff SP Oncogene; 1993 Sep; 8(9):2413-23. PubMed ID: 8361756 [TBL] [Abstract][Full Text] [Related]
19. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Aguirre-Ghiso JA; Frankel P; Farias EF; Lu Z; Jiang H; Olsen A; Feig LA; de Kier Joffe EB; Foster DA Oncogene; 1999 Aug; 18(33):4718-25. PubMed ID: 10467419 [TBL] [Abstract][Full Text] [Related]